Literature DB >> 2567391

Alpha-interferon treatment of patient with hyper IgE syndrome.

G Souillet, F Rousset, J E de Vries.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2567391     DOI: 10.1016/s0140-6736(89)92823-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  8 in total

Review 1.  Interferons 1992. How much of the promise has been realised?

Authors:  M A Volz; C H Kirkpatrick
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

Review 2.  Can persistent IgE responses be suppressed?

Authors:  D M Kemeny; D Diaz-Sanchez
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

Review 3.  The role of interleukin-4 in IgE and IgG subclass formation.

Authors:  H L Spiegelberg
Journal:  Springer Semin Immunopathol       Date:  1990

4.  Regulation of IgE and IgG4 synthesis in patients with hyper IgE syndrome.

Authors:  A Ishizaka; K Joh; R Shibata; Y Wagatsuma; M Nakanishi; K Tomizawa; K Kojima; E Kandil; Y Sakiyama; S Matsumoto
Journal:  Immunology       Date:  1990-07       Impact factor: 7.397

Review 5.  Can anti-IgE be used to treat allergy?

Authors:  F M Davis; L A Gossett; K L Pinkston; R S Liou; L K Sun; Y W Kim; N T Chang; T W Chang; K Wagner; J Bews
Journal:  Springer Semin Immunopathol       Date:  1993

Review 6.  The effect of aging on host defences. Implications for therapy.

Authors:  A Scordamaglia; G Ciprandi; F Indiveri; G W Canonica
Journal:  Drugs Aging       Date:  1991 Jul-Aug       Impact factor: 3.923

Review 7.  Hyperimmunoglobulin E syndrome: Genetics, immunopathogenesis, clinical findings, and treatment modalities.

Authors:  Hassan Hashemi; Masoumeh Mohebbi; Shiva Mehravaran; Mehdi Mazloumi; Hamidreza Jahanbani-Ardakani; Seyed-Hossein Abtahi
Journal:  J Res Med Sci       Date:  2017-04-26       Impact factor: 1.852

Review 8.  Use of cytokine therapy in primary immunodeficiency.

Authors:  Sumita Roy-Ghanta; Jordan S Orange
Journal:  Clin Rev Allergy Immunol       Date:  2010-02       Impact factor: 10.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.